S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Stocks That Really, Really Need the Defense Bill to Pass
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Stocks That Really, Really Need the Defense Bill to Pass
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Stocks That Really, Really Need the Defense Bill to Pass
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Stocks That Really, Really Need the Defense Bill to Pass
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
US consumer confidence tumbles in September as American anxiety about the future grows

BriaCell Therapeutics (BCTX) Stock Forecast, Price & News

$5.56
+0.05 (+0.91%)
(As of 09/26/2023 ET)
Compare
Today's Range
$5.42
$5.69
50-Day Range
$5.42
$7.53
52-Week Range
$4.23
$8.10
Volume
28,202 shs
Average Volume
87,745 shs
Market Capitalization
$88.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00

BriaCell Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
349.6% Upside
$25.00 Price Target
Short Interest
Bearish
8.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.56) to ($1.40) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

882nd out of 963 stocks

Pharmaceutical Preparations Industry

417th out of 452 stocks


BCTX stock logo

About BriaCell Therapeutics (NASDAQ:BCTX) Stock

BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

BCTX Price History

BCTX Stock News Headlines

The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
BCTX: Pivotal Study Protocol Cleared
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
BCTX: Posters Galore at AACR
BCTX: 82% Survival Benefit
BCTX BriaCell Therapeutics Corp.
BCTX: Down in San Antone
BCTX: Fiscal Year 2022 Results
BriaCell Announces Presentation at the 2022...
See More Headlines
Receive BCTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCTX Company Calendar

Today
9/27/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
7/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCTX
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+349.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-26,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.67 per share

Miscellaneous

Free Float
12,434,000
Market Cap
$88.85 million
Optionable
Not Optionable
Beta
1.24
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. William V. Williams M.D. (Age 67)
    CEO, Pres & Director
    Comp: $710.99k
  • Mr. Gadi Levin B.Com. (Age 50)
    C.A., CPA, M.B.A., MBA, CFO & Corp. Sec.
    Comp: $247.09k
  • Dr. Miguel A. Lopez-Lago (Age 54)
    Chief Scientific Officer
    Comp: $246.62k
  • Dr. Giuseppe Del Priore M.D. (Age 61)
    M.P.H., MPH, Chief Medical Officer
    Comp: $438.86k
  • Dr. Charles Louis Wiseman FACP (Age 77)
    M.D., Founder, Principal Research Advisor & Member of Scientific Advisory Board













BCTX Stock - Frequently Asked Questions

Should I buy or sell BriaCell Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BriaCell Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BCTX shares.
View BCTX analyst ratings
or view top-rated stocks.

What is BriaCell Therapeutics' stock price forecast for 2023?

1 analysts have issued 1 year price objectives for BriaCell Therapeutics' stock. Their BCTX share price forecasts range from $25.00 to $25.00. On average, they predict the company's share price to reach $25.00 in the next year. This suggests a possible upside of 349.6% from the stock's current price.
View analysts price targets for BCTX
or view top-rated stocks among Wall Street analysts.

How have BCTX shares performed in 2023?

BriaCell Therapeutics' stock was trading at $4.37 on January 1st, 2023. Since then, BCTX stock has increased by 27.2% and is now trading at $5.56.
View the best growth stocks for 2023 here
.

When is BriaCell Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our BCTX earnings forecast
.

When did BriaCell Therapeutics IPO?

(BCTX) raised $15 million in an initial public offering on Wednesday, February 24th 2021. The company issued 3,300,000 shares at $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

What is BriaCell Therapeutics' stock symbol?

BriaCell Therapeutics trades on the NASDAQ under the ticker symbol "BCTX."

Who are BriaCell Therapeutics' major shareholders?

BriaCell Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wasatch Advisors LP (3.83%), Natixis (0.56%), K.J. Harrison & Partners Inc (0.22%), Bank of Montreal Can (0.22%), Concord Wealth Partners (0.10%) and Simplex Trading LLC (0.00%).
View institutional ownership trends
.

How do I buy shares of BriaCell Therapeutics?

Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BriaCell Therapeutics' stock price today?

One share of BCTX stock can currently be purchased for approximately $5.56.

How much money does BriaCell Therapeutics make?

BriaCell Therapeutics (NASDAQ:BCTX) has a market capitalization of $88.85 million. The company earns $-26,840,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.

How can I contact BriaCell Therapeutics?

BriaCell Therapeutics' mailing address is 3RD FLOOR BELLEVUE CENTRE 235-15TH STR, WEST VANCOUVER A1, V7T 2X1. The official website for the company is www.briacell.com. The company can be reached via phone at (604) 921-1810, via email at investors@briacell.com, or via fax at 604-921-1898.

This page (NASDAQ:BCTX) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -